BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37470794)

  • 1. Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.
    Jayash SN; Hamoudi D; Stephen LA; Argaw A; Huesa C; Joseph S; Wong SC; Frenette J; Farquharson C
    Calcif Tissue Int; 2023 Oct; 113(4):449-468. PubMed ID: 37470794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
    Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
    Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.
    Yoon SH; Grynpas M; Mitchell J
    Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids.
    Chen J; Yoon SH; Grynpas MD; Mitchell J
    Calcif Tissue Int; 2019 Feb; 104(2):182-192. PubMed ID: 30302533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice.
    Hamoudi D; Marcadet L; Piette Boulanger A; Yagita H; Bouredji Z; Argaw A; Frenette J
    Hum Mol Genet; 2019 Sep; 28(18):3101-3112. PubMed ID: 31179501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RANKL Inhibition Reduces Cardiac Hypertrophy in
    Marcadet L; Juracic ES; Khan N; Bouredji Z; Yagita H; Ward LM; Tupling AR; Argaw A; Frenette J
    Cells; 2023 Jun; 12(11):. PubMed ID: 37296659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth Hormone Increases Bone Toughness and Decreases Muscle Inflammation in Glucocorticoid-Treated Mdx Mice, Model of Duchenne Muscular Dystrophy.
    Yoon SH; Grynpas MD; Mitchell J
    J Bone Miner Res; 2019 Aug; 34(8):1473-1486. PubMed ID: 31188496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
    Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
    J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined growth hormone and insulin-like growth factor-1 rescues growth retardation in glucocorticoid-treated mdxmice but does not prevent osteopenia.
    Wood CL; van 't Hof R; Dillon S; Straub V; Wong SC; Ahmed SF; Farquharson C
    J Endocrinol; 2022 Mar; 253(2):63-74. PubMed ID: 35191394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
    Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Therapy Deflazacort/Doxycyclyne Is Better Than Deflazacort Monotherapy to Alleviate Cardiomyopathy in Dystrophin-Deficient mdx Mice.
    Pereira JA; Mauricio AF; Marques MJ; Neto HS
    J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):458-466. PubMed ID: 28793824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy.
    Yoon SH; Chen J; Grynpas MD; Mitchell J
    Bone; 2016 Sep; 90():168-80. PubMed ID: 27373502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
    Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
    J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Potential for Sulforaphane to Attenuate Gastrointestinal Dysfunction in
    Swiderski K; Read SJ; Chan AS; Chung JD; Trieu J; Naim T; Koopman R; Lynch GS
    Nutrients; 2021 Dec; 13(12):. PubMed ID: 34960110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.